Flubromazolam’s position in scientific trials is restricted as a consequence of its classification to be a designer drug. However, its results have already been reversed with the benzodiazepine antagonist flumazenil in pharmacokinetic research, furnishing insights into its clinical implications and emergency management of overdoses.It's not nece

Article Under Review

Article Under Review